U.S., Aug. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07098338) titled 'A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)' on July 04.
Brief Summary: This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.
Study Start Date: Aug. 08
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
Intervention:
DRUG: Rilvegostomig
...